Type 1 CD4+ T-cell help is required for induction of antipeptide multispecific cytotoxic T lymphocytes by a lipopeptidic vaccine in rhesus macaques

Journal of Virology

Volumn 73, Issue 5, 1999, Pages 4447-4451

  Mortara, Lorenzo ^a,c   Gras Masse, Helene ^b   Rommens, Corinne ^b   Venet, Alain ^a   Guillet, Jean Gerard ^a   Bourgault Villada, Isabelle ^a  

^a Hôpital Cochin ^*  (France)

^b INSTITUT PASTEUR DE LILLE   (France)

^c INSTITUT COCHIN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; GAG PROTEIN; NEF PROTEIN; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HELPER CELL; IMMUNOREACTIVITY; IMMUNOSTIMULATION; INTRAMUSCULAR DRUG ADMINISTRATION; LYMPHOCYTE PROLIFERATION; MACACA; MONKEY DISEASE; NONHUMAN; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032899613     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.73.5.4447-4451.1999     Document Type: Article

References (39)

1. + T cell homeostasis and function in advanced HIV disease. Science (Washington, D.C.) 277:112-116.
2. BenMohamed, L., H. Gras-Masse, A. Tartar, P. Daubersies, K. Brahimi, M. Bossus, A. Thomas, and P. Druilhe. 1997. Lipopeptide immunization without adjuvant induces potent and long-lasting B, T helper, and cytotoxic T lymphocyte responses against a malaria liver stage antigen in mice and chimpanzees. Eur. J. Immunol. 27:1242-1253.
3. + T cell help. J. Exp. Med. 186:65-70.
4. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68:6103-6110.
5. Borrow, P., H. Lewicki, X. Wei, M. S. Horwitz, N. Peffer, H. Meyers, J. A. Nelson, J. E. Gairin, B. H. Hahn, M. B. A. Oldstone, and G. M. Shaw. 1997. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat. Med. 3:205-211.
6. Bourgault, I., F. Chirat, A. Tartar, J. P. Lévy, J. G. Guillet, and A. Venet. 1994. Simian immunodeficiency virus as a model for vaccination against HIV. Induction in rhesus macaques of GAG-or NEF-specific cytotoxic T lymphocytes by lipopeptides. J. Immunol. 152:2530-2537.
7. Bourgault-Villada, I., L. Mortara, A. M. Aubertin, H. Gras-Masse, J. P. Lévy, and J. G. Guillet. 1997. Positive role of macaque cytotoxic T lymphocytes during SIV infection: decrease of cellular viremia and increase of asymptomatic clinical period. FEMS Immunol. Med. Microbiol. 19:81-87.
8. Byrne, J. A., and M. B. A. Oldstone. 1984. Biology of cloned cytotoxic T lymphocytes specific for lymphocytic choriomeningitis virus: clearance of virus in vivo. J. Virol. 51:682-686.
9. Del Guercio, M. F., J. Alexander, R. T. Kubo, T. Arrhenius, A. Maewal, E. Appella, S. L. Hoffman, T. Jones, D. Valmori, K. Sakaguchi, H. M. Grey, and A. Sette. 1997. Potent immunogenic short linear peptide constructs composed of B cell epitopes and Pan DR T helper epitopes (PADRE) for antibody responses in vivo. Vaccine 15:441-448.
10. Deprez, B., J. P. Sauzet, C. Boutillon, F. Martinon, A. Tartar, C. Sergheraert, J. G. Guillet, E. Gomard, and H. Gras-Masse. 1996. Comparative efficiency of simple lipopeptide constructs for in vivo induction of virus-specific CTL. Vaccine 14:375-382.
11. Deres. K., H. Schild, K. H. Wiesmüller, G. Jung, and H. G. Rammensee. 1989. In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature (London) 342:561-564.
12. + nef-specific cytotoxic T cells in vaccinated macaques. Nat. Med. 1:1167-1173.
13. + repertoire during antiviral therapy. Nat. Med. 4:215-221.
14. Goulder, P. J. R., R. E. Phillips, R. A. Colbert, S. McAdam, G. Ogg, M. A. Nowak, P. Giangrande, G. Luzzi, B. Morgan, A. Edwards, A. J. McMichael, and S. Rowland-Jones. 1997. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat. Med. 3:212-217.
15. Herrington, D. A., D. F. Clyde, G. Losonsky, M. Cortesia, J. R. Murphy, J. Davis, S. Baqar, A. M. Felix, E. P. Heimer, D. Gillessen, E. Nardin, R. S. Nussenzweig, V. Nussenzweig, M. R. Hollingdale, and M. M. Levine. 1987. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature (London) 328:257-259.
16. Keene, J. A., and J. Forman. 1982. Helper activity is required for the in vivo generation of cytotoxic T lymphocytes. J. Exp. Med. 155:768-782.
17. Klein, M. R., C. A. van Baalen, A. M. Holwerda, S. R. Kerkhof Garde, R. J. Bende, I. P. M. Keet, J. K. M. Eeftinck-Schattenkerk, A. D. M. E. Osterhaus, H. Schuitemaker, and F. Miedema. 1995. Kinetics of gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J. Exp. Med. 181:1365-1372.
18. Koup, R. A., J. T. Safrit, Y. Cao, C. A. Andrews, G. McLeod, W. Borkowsky, C. Farthing, and D. D. Ho. 1994. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68:4650-4655.
19. Lasarte, J. J., P. Sarobe, A. Gullon, J. Prieto, and F. Borras-Cuesta. 1992. Induction of cytotoxic T lymphocytes in mice against the principal neutralizing domain of HIV-1 by immunization with an engineered T-cytotoxic-T-helper synthetic peptide construct. Cell. Immunol. 141:211-218.
20. Livingston, B. D., C. Crimi, H. Grey, G. Ishioka, F. V. Chisari, J. Fikes, H. Grey, R. W. Chesnut, and A. Sette. 1997. The hepatitis B virus-specific CTL responses induced in humans by lipopeptide vaccination are comparable to those elicited by acute viral infection. J. Immunol. 159:1383-1392.
21. Loing, E., A. Delannoye, C. Sergheraert, A. Tartar, and H. Gras-Masse. 1996. Assessing cytoplasm delivery of lipopeptides into intact cells by a functional assay based on PKC inhibition. I. The Jurkat model. Pept. Res. 9: 229-232.
22. Martinon, F., H. Gras-Masse, C. Boutillon, F. Chirat, B. Deprez, J. G. Guillet, E. Gomard, A. Tartar, and J. P. Lévy. 1992. Immunization of mice with lipopeptides bypasses the prerequisite for adjuvant. Immune response of BALB/c mice to human immunodeficiency virus envelope glycoprotein. J. Immunol. 149:3416-3422.
23. Mortara, L., F. Letourneur, H. Gras-Masse, A. Venet, J.-G. Guillet, and I. Bourgault-Villada. 1998. Selection of virus variants and emergence of virus escape mutants after immunization with an epitope vaccine. J. Virol. 72: 1403-1410.
24. Ossendorp, F., E. Mengedé, M. Camps, R. Filius, and C. J. M. Melief. 1998. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J. Exp. Med. 187:693-702.
25. Ostankovitch, M., G. Guichard, F. Connan, S. Muller, A. Chaboissier, J. Hoebeke, J. Choppin, J. P. Briand, and J. G. Guillet. 1998. A partially modified retro-inverso pseudopeptide modulates the cytokine profile of CTL specific for an influenza virus epitope. J. Immunol. 161:200-208.
26. O'Sullivan, D., T. Arrhenius, J. Sidney, M. F. Del Guercio, M. Albertson, M. Wall, C. Oseroff, S. Southwood, S. M. Colon, F. C. A. Gaela, and A. Sette. 1991. On the interaction of promiscuous antigenic peptides with different DR alleles. Identification of common structural motifs. J. Immunol. 147: 2663-2669.
27. Panina-Bordignon, P., A. Tan, A. Termijtelen, S. Demotz, G. Corradin, and A. Lanzavecchia. 1989. Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur. J. Immunol. 19:2237-2242.
28. Price, D. A., P. J. R. Goulder, P. Klenerman, A. K. Sewell, P. J. Easterbrook, M. Troop, C. R. M. Bangham, and R. E. Phillips. 1997. Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proc. Natl. Acad. Sci. USA 94:1890-1895.
29. + T lymphocytes induced by peptide immunization: an ex vivo analysis. Int. Immunol. 10:1273-1279.
30. + T cell responses associated with control of viremia. Science (Washington, D.C.) 278:1447-1450.
31. Rubistein, A., H. Goldstein, M. Pettoello-Mantovani, Y. Mizrachi, B. R. Bloom, E. Furer, B. Althaus, J. U. Que, T. Hasler, and S. J. Cryz. 1995. Safety and immunogenicity of a V3 loop synthetic peptide conjugated to purified protein derivative in HIV-seronegative volunteers. AIDS 9:243-251.
32. Sauzet, J. P., H. Gras-Masse, J. G. Guillet, and E. Gomard. 1996. Influence of strong CD4 epitope on long-term virus-specific cytotoxic T cell responses induced in vivo with peptides. Int. Immunol. 8:457-465.
33. Scheibenbogen, C., K. H. Lee, S. Stevanovic, M. Witzens, M. Willhauck, V. Waldmann, H. Naeher, H. G. Rammensee, and U. Keilholz. 1997. Analysis of the T cell response to tumor and viral peptide antigens by an IFNγ-ELIS-POT assay. Int. J. Cancer 71:932-936.
34. Schulz, M., R. M. Zinkernagel, and H. Hengartner. 1991. Peptide-induced antiviral protection by cytotoxic T cells. Proc. Natl. Acad. Sci. USA 88:991-993.
35. + CTL in vivo with peptide vaccine constructs. J. Immunol. 152:549-556.
36. Stuhler, G., and S. F. Schlossman. 1997. Antigen organization regulates cluster formation and induction of cytotoxic T lymphocytes by helper T cell subsets. Proc. Natl. Acad. Sci. USA 94:622-627.
37. Taylor, P. M., and B. A. Askonas. 1986. Influenza nucleoprotein-specific cytotoxic T-cell clones are protective in vivo. Immunology 58:417-420.
38. Thiam, K., E. Loing, F. Gilles, C. Verwaerde, B. Quatannens, C. Auriault, and H. Gras-Masse. 1997. Induction of apoptosis by protein kinase C pseudosubstrate lipopeptides in several human cells. Lett. Pept. Sci. 4:397-402.
39. Vitiello, A., G. Ishioka, H. M. Grey, R. Rose, P. Farness, R. LaFond, L. Yuan, F. V. Chisari, J. Furze, R. Bartholomeuz, and R. W. Chesnut. 1995. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. J. Clin. Investig. 95:341-349.